Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

Schedule of reconciliation of cash and cash equivalents and restricted cash

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets:

	June 30, 2023		December 31, 2022		June 30, 2022		December 31, 2021
Cash and cash equivalents	$	3,237,176	$	7,440,030	$	16,586,577	$	36,080,392
Restricted cash		496,894		495,629		441,320		551,794
Total cash and cash equivalents and restricted cash in the condensed consolidated statements of cash flows	$	3,734,070	$	7,935,659	$	17,027,897	$	36,632,186

Schedule of inventories

Inventories are valued using the first-in, first-out cost method and stated at the lower of cost or net realizable value and consist of the following:

	June 30, 2023		December 31, 2022
Raw materials and supplies	$	1,254,776	$	1,011,476
Work-in-process		28,069		37,445
Finished goods		2,061,920		2,596,830
Total	$	3,344,765	$	3,645,751

Schedule of finite-lived and indefinite-lived intangible assets

Intangible assets include trademarks, developed technology and software, in-process research & development (“IPR&D”), and distributor relationships and consisted of the following as of June 30, 2023 and December 31, 2022:

				June 30, 2023								December 31, 2022
	Subsidiary	Cost		Accumulated Amortization and Impairment			Effect of Foreign Exchange Rates			Net Balance		Accumulated Amortization and Impairment			Effect of Foreign Exchange Rates			Net Balance
Trademarks and tradenames	Curetis	$	1,768,000	$	(564,679	)	$	(30,541	)	$	1,172,780	$	(469,011	)	$	(62,520	)	$	1,236,469
Distributor relationships	Curetis		2,362,000		(502,936	)		(40,799	)		1,818,265		(417,728	)		(83,525	)		1,860,747
A50 – Developed technology	Curetis		349,000		(159,254	)		(6,029	)		183,717		(132,273	)		(12,342	)		204,385
Ares – Developed technology	Ares Genetics		5,333,000		(1,216,613	)		(84,767	)		4,031,620		(1,010,495	)		(183,132	)		4,139,373
A30 – In-Process Research & Development	Curetis		5,706,000		(5,607,434	)		(98,566	)		—		(5,407,699	)		(298,301	)		—
		$	15,518,000	$	(8,050,916	)	$	(260,702	)	$	7,206,382	$	(7,437,206	)	$	(639,820	)	$	7,440,974

Schedule of estimated useful lives of identifiable intangible assets

Identifiable intangible assets are amortized on a straight-line basis over their estimated useful lives. The estimated useful lives of the intangibles are:

	Estimated Useful Life
Trademarks and tradenames	10 years
Customer/distributor relationships	15 years
A50 – Developed technology	7 years
Ares – Developed technology	14 years
A30 – Acquired in-process research & development	Indefinite

Schedule of expected amortization of intangible assets

Expected future amortization of intangible assets is as follows:

Year Ending December 31,
2023 (July to December)	$	375,920
2024		751,840
2025		751,840
2026		751,840
2027		715,051
Thereafter		3,859,891
Total	$	7,206,382